Your browser doesn't support javascript.
loading
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Vergote, Ignace; Heitz, Florian; Buderath, Paul; Powell, Matthew; Sehouli, Jalid; Lee, Christine M; Hamilton, Anne; Fiorica, James; Moore, Kathleen N; Teneriello, Michael; Golden, Lisa; Zhang, Wei; Pitou, Celine; Bell, Robert; Campbell, Robert; Farrington, Daphne L; Bell-McGuinn, Katherine; Wenham, Robert M.
Afiliação
  • Vergote I; University Hospital Leuven, Leuven Cancer Institute, Gynaecological Oncology, Leuven, Belgium. Electronic address: Ignace.vergote@uzleuven.be.
  • Heitz F; Kliniken Essen-Mitte, Evangelische Huyssenstiftung, Essen, Germany; Charité Campus Virchow Klinikum / Department of Gynecology and Oncological Surgery, Berlin, Germany.
  • Buderath P; Universitätsklinikum Essen, Essen, Germany.
  • Powell M; Barnes Jewish Hospital, St Louis, MO, USA.
  • Sehouli J; Charité Campus Virchow Klinikum / Department of Gynecology and Oncological Surgery, Berlin, Germany.
  • Lee CM; Texas Oncology - Woodlands, The Woodlands, TX, USA.
  • Hamilton A; Royal Women's Hospital/ Peter MacCallum Cancer Centre, Parkville, Melbourne, Victoria, Australia.
  • Fiorica J; Sarasota Memorial Hospital, Sarasota, FL, USA.
  • Moore KN; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA/Sarah Cannon Research Institute, Nashville, TN, USA.
  • Teneriello M; Texas Oncology - Austin, Austin, TX, USA.
  • Golden L; Eli Lilly and Company, Indianapolis, IN, USA.
  • Zhang W; Eli Lilly and Company, Indianapolis, IN, USA.
  • Pitou C; Eli Lilly and Company, Erl Wood, Windlesham, Surrey, UK.
  • Bell R; Eli Lilly and Company, Indianapolis, IN, USA.
  • Campbell R; Eli Lilly and Company, Indianapolis, IN, USA.
  • Farrington DL; Eli Lilly and Company, Indianapolis, IN, USA.
  • Bell-McGuinn K; Eli Lilly and Company, Indianapolis, IN, USA.
  • Wenham RM; Moffitt Cancer Center, Tampa, FL, USA.
Gynecol Oncol ; 156(1): 23-31, 2020 01.
Article em En | MEDLINE | ID: mdl-31791552
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Epitelial do Ovário / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Epitelial do Ovário / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article